The Role of Immunotherapy in the Management of Patients with Malignant Melanoma

Overview

Journal World J Surg

Publisher Wiley

Specialty General Surgery

Date 1979 Jul 30

PMID 382645

Citations 3

Authors

J E Goodnight Jr

D L Morton

Affiliations

Soon will be listed here.

Citing Articles

Therapeutic vaccination immunomodulation: forming the basis of all cancer immunotherapy.

Coventry B Ther Adv Vaccines Immunother. 2019; 7:2515135519862234.

PMID: 31414074 PMC: 6676259. DOI: 10.1177/2515135519862234.

General surgery-important advances in clinical medicine: cutaneous melanoma.

Thompson R, Branson B West J Med. 1983; 138(2):244.

PMID: 18749293 PMC: 1010691.

Adjuvant BCG immunotherapy for malignant melanoma.

Paterson A, Willans D, Jerry L, Hanson J, McPherson T Can Med Assoc J. 1984; 131(7):744-8.

PMID: 6383591 PMC: 1483595.

References

Rosenberg S, Seipp C, Sears H . Clinical and immunologic studies of disseminated BCG infection. Cancer. 1978; 41(5):1771-80. DOI: 10.1002/1097-0142(197805)41:5<1771::aid-cncr2820410519>3.0.co;2-c. View

Fossati G, Colnaghi M, Porta G, Cascinelli N, Veronesi U . Cellular and humoral immunity against human malignant melanoma. Int J Cancer. 1971; 8(2):344-50. DOI: 10.1002/ijc.2910080221. View

Krementz E, Mansell P, HORNUNG M, SAMUELS M, Sutherland C, Benes E . Proceedings: Immunotherapy of malignant disease: the use of viable sensitized lymphocytes or transfer factor prepared from sensitized lymphocytes. Cancer. 1974; 33(2):394-401. DOI: 10.1002/1097-0142(197402)33:2<394::aid-cncr2820330214>3.0.co;2-p. View

SUMNER W, Foraker A . Spontaneous regression of human melanoma: clinical and experimental studies. Cancer. 1960; 13:79-81. DOI: 10.1002/1097-0142(196001/02)13:1<79::aid-cncr2820130115>3.0.co;2-4. View

Cohen M, Jessup J, Felix E, Weese J, Herberman R . Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene. Cancer. 1978; 41(6):2456-63. DOI: 10.1002/1097-0142(197806)41:6<2456::aid-cncr2820410654>3.0.co;2-b. View

Israel L, Depierre A, Edelstein R, CROS-DECAM J, Maury P . Effect of intranodular B.C.G. in 22 melanoma patients. Panminerva Med. 1975; 17(5-6):187-8. View

CURRIE G, McElwain T . Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study. Br J Cancer. 1975; 31(2):143-56. PMC: 2009407. DOI: 10.1038/bjc.1975.19. View

Morton D, Eilber F, Malmgren R, Wood W . Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery. 1970; 68(1):158-63; discussion 163-4. View

JEWELL W, Thomas J, Sterchi J, Morse P, HUMPHREY L . Critical analysis of treatment of stage II and stage III melanoma patients with immunotherapy. Ann Surg. 1976; 183(5):543-9. PMC: 1344342. DOI: 10.1097/00000658-197605000-00011. View

10.

Newton K, Westbury G, Lacey B . Use of vaccinia virus in the treatment of metastatic malignant melanoma. Br Med J. 1970; 2(5708):512-5. PMC: 1700360. DOI: 10.1136/bmj.2.5708.512. View

11.

Wallack M, Steplewski Z, KOPROWSKI H, Rosato E, George J, Hulihan B . A new approach in specific, active immunotherapy. Cancer. 1977; 39(2):560-4. DOI: 10.1002/1097-0142(197702)39:2<560::aid-cncr2820390227>3.0.co;2-m. View

12.

NADLER S, Moore G . Immunotherapy of malignant disease. Arch Surg. 1969; 99(3):376-81. DOI: 10.1001/archsurg.1969.01340150084016. View

13.

Morton D, Malmgren R, Holmes E, KETCHAM A . Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery. 1968; 64(1):233-40. View

14.

Everall K, Dowd P, Davies D, ONEILL G, ROWLAND G . Treatment of melanoma by passive humoral immunotherapy using antibody drug synergism. Lancet. 1977; 1(8021):1105-6. DOI: 10.1016/s0140-6736(77)92359-5. View

15.

Eilber F, Morton D, Holmes E, Sparks F, Ramming K . Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma. N Engl J Med. 1976; 294(5):237-40. DOI: 10.1056/NEJM197601292940501. View

16.

Smith G, Morse Jr P, Deraps G, Raju S, HARDY J . Immunotherapy of patients with cancer. Surgery. 1973; 74(1):59-68. View

17.

Mastrangelo M, Sulit H, Prehn L, BORNSTEIN R, Yarbro J, Prehn R . Intralesional BCG in the treatment of metastatic malignant melanoma. Cancer. 1976; 37(2):684-92. DOI: 10.1002/1097-0142(197602)37:2<684::aid-cncr2820370212>3.0.co;2-y. View

18.

Bast Jr R, Zbar B, Borsos T, Rapp H . BCG and cancer (first of two parts). N Engl J Med. 1974; 290(25):1413-20. DOI: 10.1056/NEJM197406202902506. View

19.

NATHANSON L . Regression of intradermal malignant melanoma after intralesional injection of Mycobacterium bovis strain BCG. Cancer Chemother Rep. 1972; 56(5):659-65. View

20.

Pinsky C, Hirshaut Y, Oettgen H . Treatment of malignant melanoma by intratumoral injection of BCG. Natl Cancer Inst Monogr. 1973; 39:225-8. View